Cargando…

Circulating C1q/TNF-Related Protein 3, Omentin-1 and NGAL in Obese Patients with Type 2 Diabetes During Insulin Therapy

The aim of the study was to quantify the plasma concentration of omentin-1, neutrophil gelatinase-associated lipocalin (NGAL), and complement C1q tumor necrosis factor-related protein-3 (CTRP3) in obese patients with type 2 diabetes, before introducing insulin therapy, in relation to the plasma expr...

Descripción completa

Detalles Bibliográficos
Autores principales: Komosinska-Vassev, Katarzyna, Olczyk, Pawel, Kuźnik-Trocha, Kornelia, Jura-Półtorak, Agnieszka, Derkacz, Alicja, Purchałka, Marcin, Telega, Alicja, Olczyk, Krystyna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617185/
https://www.ncbi.nlm.nih.gov/pubmed/31195747
http://dx.doi.org/10.3390/jcm8060805
_version_ 1783433633605877760
author Komosinska-Vassev, Katarzyna
Olczyk, Pawel
Kuźnik-Trocha, Kornelia
Jura-Półtorak, Agnieszka
Derkacz, Alicja
Purchałka, Marcin
Telega, Alicja
Olczyk, Krystyna
author_facet Komosinska-Vassev, Katarzyna
Olczyk, Pawel
Kuźnik-Trocha, Kornelia
Jura-Półtorak, Agnieszka
Derkacz, Alicja
Purchałka, Marcin
Telega, Alicja
Olczyk, Krystyna
author_sort Komosinska-Vassev, Katarzyna
collection PubMed
description The aim of the study was to quantify the plasma concentration of omentin-1, neutrophil gelatinase-associated lipocalin (NGAL), and complement C1q tumor necrosis factor-related protein-3 (CTRP3) in obese patients with type 2 diabetes, before introducing insulin therapy, in relation to the plasma expression profiles of these regulatory molecules in the same patients after a 6-month insulin mixture therapy and in obese controls. Elevated plasma NGAL concentrations were found in type 2 diabetic patients as compared with subjects with metabolically healthy obesity. In turn, a 6-month insulin mixture therapy has shown a marked increase in the plasma concentration of omentine-1 and a significant decrease in plasma CTRP3 concentration in obese patients with type 2 diabetes, in relation to the values found in these patients before the implementation of insulin therapy. Insulin mixture therapy has also proved to be an important factor modifying the plasma profile of NGAL, increasing the concentration of this bioactive molecule in the plasma of patients with type 2 diabetes, after 6 months of its use, in relation to the concentration before treatment. The significant changes in the plasma profile of omentin-1, NGAL and CTRP3 during insulin therapy suggest their potential diagnostic utility in monitoring metabolic changes associated with the introduction of insulin treatment in type 2 diabetic patients.
format Online
Article
Text
id pubmed-6617185
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-66171852019-07-18 Circulating C1q/TNF-Related Protein 3, Omentin-1 and NGAL in Obese Patients with Type 2 Diabetes During Insulin Therapy Komosinska-Vassev, Katarzyna Olczyk, Pawel Kuźnik-Trocha, Kornelia Jura-Półtorak, Agnieszka Derkacz, Alicja Purchałka, Marcin Telega, Alicja Olczyk, Krystyna J Clin Med Article The aim of the study was to quantify the plasma concentration of omentin-1, neutrophil gelatinase-associated lipocalin (NGAL), and complement C1q tumor necrosis factor-related protein-3 (CTRP3) in obese patients with type 2 diabetes, before introducing insulin therapy, in relation to the plasma expression profiles of these regulatory molecules in the same patients after a 6-month insulin mixture therapy and in obese controls. Elevated plasma NGAL concentrations were found in type 2 diabetic patients as compared with subjects with metabolically healthy obesity. In turn, a 6-month insulin mixture therapy has shown a marked increase in the plasma concentration of omentine-1 and a significant decrease in plasma CTRP3 concentration in obese patients with type 2 diabetes, in relation to the values found in these patients before the implementation of insulin therapy. Insulin mixture therapy has also proved to be an important factor modifying the plasma profile of NGAL, increasing the concentration of this bioactive molecule in the plasma of patients with type 2 diabetes, after 6 months of its use, in relation to the concentration before treatment. The significant changes in the plasma profile of omentin-1, NGAL and CTRP3 during insulin therapy suggest their potential diagnostic utility in monitoring metabolic changes associated with the introduction of insulin treatment in type 2 diabetic patients. MDPI 2019-06-05 /pmc/articles/PMC6617185/ /pubmed/31195747 http://dx.doi.org/10.3390/jcm8060805 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Komosinska-Vassev, Katarzyna
Olczyk, Pawel
Kuźnik-Trocha, Kornelia
Jura-Półtorak, Agnieszka
Derkacz, Alicja
Purchałka, Marcin
Telega, Alicja
Olczyk, Krystyna
Circulating C1q/TNF-Related Protein 3, Omentin-1 and NGAL in Obese Patients with Type 2 Diabetes During Insulin Therapy
title Circulating C1q/TNF-Related Protein 3, Omentin-1 and NGAL in Obese Patients with Type 2 Diabetes During Insulin Therapy
title_full Circulating C1q/TNF-Related Protein 3, Omentin-1 and NGAL in Obese Patients with Type 2 Diabetes During Insulin Therapy
title_fullStr Circulating C1q/TNF-Related Protein 3, Omentin-1 and NGAL in Obese Patients with Type 2 Diabetes During Insulin Therapy
title_full_unstemmed Circulating C1q/TNF-Related Protein 3, Omentin-1 and NGAL in Obese Patients with Type 2 Diabetes During Insulin Therapy
title_short Circulating C1q/TNF-Related Protein 3, Omentin-1 and NGAL in Obese Patients with Type 2 Diabetes During Insulin Therapy
title_sort circulating c1q/tnf-related protein 3, omentin-1 and ngal in obese patients with type 2 diabetes during insulin therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617185/
https://www.ncbi.nlm.nih.gov/pubmed/31195747
http://dx.doi.org/10.3390/jcm8060805
work_keys_str_mv AT komosinskavassevkatarzyna circulatingc1qtnfrelatedprotein3omentin1andngalinobesepatientswithtype2diabetesduringinsulintherapy
AT olczykpawel circulatingc1qtnfrelatedprotein3omentin1andngalinobesepatientswithtype2diabetesduringinsulintherapy
AT kuzniktrochakornelia circulatingc1qtnfrelatedprotein3omentin1andngalinobesepatientswithtype2diabetesduringinsulintherapy
AT jurapołtorakagnieszka circulatingc1qtnfrelatedprotein3omentin1andngalinobesepatientswithtype2diabetesduringinsulintherapy
AT derkaczalicja circulatingc1qtnfrelatedprotein3omentin1andngalinobesepatientswithtype2diabetesduringinsulintherapy
AT purchałkamarcin circulatingc1qtnfrelatedprotein3omentin1andngalinobesepatientswithtype2diabetesduringinsulintherapy
AT telegaalicja circulatingc1qtnfrelatedprotein3omentin1andngalinobesepatientswithtype2diabetesduringinsulintherapy
AT olczykkrystyna circulatingc1qtnfrelatedprotein3omentin1andngalinobesepatientswithtype2diabetesduringinsulintherapy